The Human SARS-CoV-2 Spike (Trimer) Ig Total ELISA is a serology assay that measures and quantifies immunoglobulin (Ig) antibodies against SARS-CoV-2 Spike (Trimer) in human serum or plasma.
Principle of the method
The SARS-CoV-2 Spike (Trimer) Ig Human Enzyme-Linked Immunosorbent Assay (Enzyme-Linked Immunosorbent Assay) is designed to measure the amount of Ig antibodies bound to SARS-CoV-2 Spike (Trimer). A trimerized Spike protein is precoated in the wells of the supplied microplate. Samples, controls, including a high control that can be used as a standard, are added to these wells and bound to immobilized (capture) Spike protein.
The wells are washed and HRP-conjugated Ig antibodies are added and will bind to any captured antibodies. The Ig Total antibody recognizes IgG, IgM, and IgA. The wells are washed and a substrate solution is added that reacts with the enzyme complex to produce a measurable signal. The intensity of this signal is directly proportional to the concentration of antibodies present in the original sample.
SARS (severe acute respiratory syndrome) has recently been shown to be caused by a human coronavirus. Human coronaviruses are the leading cause of upper respiratory diseases, such as the common cold, in humans. Coronaviruses are positive-strand RNA viruses, which have the largest viral RNA genomes known to date (27-31 kb).
The first step in coronavirus infection is the binding of the viral spike protein, a 139 kDa protein, to certain receptors on host cells. The spike protein is the main surface antigen of the coronavirus. Glycosylated peak protein (as well as nucleocapsid protein) can be detected in cell culture supernatants infected with antisera from SARS patients.
For research use only. It should not be used in diagnostic procedures. Resale prohibited without express authorization.